Liminatus Pharma Inc. (NASDAQ:LIMN) Short Interest Update

Liminatus Pharma Inc. (NASDAQ:LIMN) saw a large decrease in short interest during the month of September. As of September 15th, there was short interest totaling 58,817 shares, a decrease of 38.4% from the August 31st total of 95,505 shares. Currently, 5.4% of the shares of the company are short sold. Based on an average daily trading volume, of 27,526 shares, the days-to-cover ratio is currently 2.1 days.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on LIMN shares. Wall Street Zen lowered shares of Liminatus Pharma to a “strong sell” rating in a research note on Saturday, August 22nd. Weiss Ratings cut Liminatus Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Liminatus Pharma Trading Down 0.8%

Shares of LIMN traded down $0.03 during trading hours on Thursday, reaching $3.70. The company had a trading volume of 20,465 shares, compared to its average volume of 354,861. Liminatus Pharma has a 12-month low of $3.29 and a 12-month high of $141.50. The firm has a 50 day simple moving average of $4.68 and a 200-day simple moving average of $7.07. The company has a market capitalization of $4.96 million, a price-to-earnings ratio of -0.16 and a beta of 5.30.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for serious diseases with significant unmet medical needs.

The company’s primary activities involve advancing pharmaceutical candidates through research and development, including preclinical and clinical testing. Publicly available information indicates that its work is centered on potential treatments in areas such as oncology and related therapeutic applications, rather than on marketed commercial products.

Liminatus Pharma is listed on the Nasdaq under the symbol LIMN.